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Introduction
Glaucoma is a potentially blinding disease caused by progressive and irreversible optic 
neuropathy. The number of persons worldwide estimated to become blind as a result of 
primary glaucoma is 4.5 million, which accounts for more than 12% of all global blindness.1 
The two major types of glaucoma based on the anatomy of the drainage angle in the eye 
are primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG). 
While POAG is an insidious disease, PACG can go through a highly symptomatic acute 
stage known as an acute angle closure attack which is also termed acute angle closure 
glaucoma. This article reviews several retrospective case series and case reports on acute 
PACG induced by local and systemic medications. Acute angle closure is caused mainly by 
the natural distortion of the anterior segment of the eyeball predisposing an individual to 
sudden occlusion of the drainage angle. An acute attack of angle closure can be triggered 
by dilatation of the pupil leading to blockage of the angle by the iris tissue. Local and 
systemic medications that possess mydriatic effect have the potential to precipitate such 
an attack acute. The risk is higher in subjects predisposed to the development of angle 
closure. These subjects may have a shorter eyeball, larger crystalline lens, shallower 
anterior chamber, and a narrower drainage angle than normal subjects. In which case 
acute angle closure is a potentially blinding side-effect of many local and systemic drugs, 
including antipsychotics, antidepressants, monoamine oxidase inhibitors, anti-histamines, 
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黎少明
 Objective To review acute angle closure attacks induced by local and 
systemic medications.
 Data sources PubMed literature searches up to August 2011.
 Study selection The following key words were used for the search: “drug”, 
“iatrogenic”, “acute angle closure glaucoma”.
 Data extraction A total of 86 articles were retrieved using the key words. Only 
those concerning acute angle closure attack triggered by local or 
systemic drug administration were included. For articles on the 
same or related topics, those published at later or more recent 
dates were selected. As a result, 44 articles were included and 
formed the basis of this review.
 Data synthesis An acute attack of angle closure can be triggered by dilatation 
of the pupil, by anatomical changes in the ciliary body and iris, 
or by movement of the iris-lens diaphragm. Local and systemic 
medications that cause these changes have the potential to 
precipitate an attack of acute angle closure. The risk is higher 
in subjects who are predisposed to the development of angle 
closure. Many pharmaceutical agents including ophthalmic 
eyedrops and systemic drugs prescribed by general practitioners 
and various specialists (in psychiatry, otorhinolaryngology, 
ophthalmology, medicine, and anaesthesia) can precipitate 
an acute angle closure attack. The medications include: 
anti-histamines, anti-epileptics, antiparkinsonian agents, 
antispasmolytic drugs, mydriatic agents, sympathetic agents, 
and botulinum toxin.
  Conclusion Since acute angle closure attack is a potentially blinding eye 
disease, it is extremely important to be vigilant and aware of 
ophthalmic and systemic medications that can lead to such 
attacks in predisposed subjects and to diagnose the condition 
when it occurs.
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 目的 回顧因局部及全身性藥物引致急性閉角型青光眼的文
獻。
 資料來源 在醫學資料庫PubMed中搜尋至2011年8月發表的文
獻。
 研究選取 用以搜索文獻的關鍵詞為「藥物」（drug）、「醫
原性的」（ iatrogenic）及「急性閉角型青光眼」
（acute angle closure glaucoma）。
 資料選取 利用關鍵詞共搜索到86篇文章。其中只揀選與局部及
全身性藥物引致急性閉角型青光眼相關的文獻。遇上
有類似課題的文獻，只會選擇近期發表的資料。最後
揀選了44篇文章成為本文的基礎。
 資料綜合 急性閉角型青光眼可能是由於瞳孔放大而誘發、睫狀
體和虹膜形狀有變、以及晶狀體－虹膜隔的移動所
致。凡局部及全身性藥物能夠引致這些反應的都有機
會導致急性閉角型青光眼。對於容易患有此症的人士
來說，誘發的風險更高。很多藥物都可能促成急性閉
角型青光眼，包括全科及各專科醫生（精神科、耳鼻
喉科、眼科、內科及麻醉科）處方的滴眼液及全身性
藥物。這些藥物包括抗組織胺、抗癲癇藥、抗震顫麻
痺藥、抗痙攣藥、擴瞳劑、交感性眼藥及肉毒杆菌毒
素。
 結論 急性閉角型青光眼有可能導致失明，所以醫生處理容
易患有閉角型青光眼的人時，對於一些可能導致青光
眼的眼部及全身性藥物要加倍小心謹慎。當有病徵時
要盡早為病人診斷。
藥物引致的急性閉角型青光眼
antiparkinsonian agents, antispasmolytics, anti-
epileptic drugs, mydriatic agents, sympathomymetics, 
and botulinum toxin. 
Methods
A PubMed search of literature up to August 2011 was 
conducted using the following key words: “acute 
angle closure glaucoma”, “iatrogenic”, and “drugs”. 
A total of 86 articles were retrieved. Only those 
concerning acute angle closure attack triggered by 
local or systemic drug administration were included. 
During article selection, prospective studies had 
a higher ranking than retrospective studies, and 
case reports were also included. For articles on the 
same or related topics, those published at later or 
more recent dates were selected. In all, 44 articles 
were included and formed the basis of this review. 
These include 36 case reports, four review articles, 
three prospective non-controlled studies, and 
one prospective controlled trial. Other references 
were also cited for the background and related 
information of this review article. These included 
seven prospective non-controlled studies, one 
prospective controlled trial, three retrospective case 
series, and five review articles.
Highlights of literature review
Acute angle closure 
Acute angle closure attack, formerly termed acute 
angle closure glaucoma, is sight-threatening and 
symptomatic, and is characterised by a sudden and 
marked rise in the intraocular pressure (IOP) due to 
obstruction of aqueous humour outflow. Symptoms 
during the acute attack include severe headache and 
ocular pain with nausea and vomiting and blurring of 
vision. The attacked eye is red and the pupil is semi-
dilated. This is in contrast to the open angle glaucoma 
which runs an insidious and relatively asymptomatic 
course. A single episode of an acute angle closure 
attack can cause blindness, reduction in visual 
acuity, visual field loss, and glaucomatous optic 
neuropathy.2-4 It can also lead to corneal damage, 
cataracts, and iris atrophy.5,6 Acute angle closure 
attack is defined as: (1) eyes with IOP of above 21 mm 
Hg together with the presence of three or more of 
the following clinical signs: conjunctival injection, 
iris bombe, corneal epithelial oedema, mid-dilated 
unreactive pupil, and a shallow anterior chamber; 
(2) patients experience at least two of the following 
symptoms: ocular pain, nausea and/or vomiting, 
blurred vision, and seeing halos; (3) occluded angle 
in the attacked eye.7
Risks factors for the development of acute angle 
closure attack
Ethnic differences appear to be an important risk 
in the development of acute angle closure attacks; 
Asians are at higher risk than Caucasians. Among 
Asians, a Singapore study revealed that Chinese are 
at higher risk than the Malay and Indians.8 However, 
information on the inheritance of acute angle closure 
attack is limited. A study in Caucasians suggested 
that familial incidence of PACG was rare but it had 
a degree of genetic predisposition, and the disease 
was triggered by environmental factors.9 However, 
in a recent study on the heritability and sibling risk 
of narrow angles in Asians that consisted of mainly 
Chinese, it was found to be highly heritable. This 
was noted in 58.5% first-degree relatives of patients 
with PAC (primary angle closure with elevation of the 
IOP without evidence of glaucomatous optic nerve 
damage) and PACG (primary angle closure with 
elevation of the IOP and glaucomatous optic nerve 
damage). The recurrence risk of siblings having 
narrow angles was 49%. The relative risk of siblings 
having narrow angles was 6.57 times higher than the 
general population.10 
 Elderly women are at highest risk of developing 
acute angle closure attacks.8,11-13 Seasonal factors have 
also been found to be associated with acute angle 
closure attacks; the frequency was higher in autumn 
and winter than in spring and summer.11
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FIG 1.  Anterior segment optical coherence tomographic image showing anterior segment structures under physiological conditions
FIG 2.  Anterior segment optical coherence tomographic image showing anterior segment structures after pupil dilatation.  The iris 
bunched up at the angle causing narrowing of the angle
 Patients with narrow irido-corneal angles 
are at high risk. Eyes with shallow anterior chamber 
depth, shorter axial length and a thicker lens as 
compared to normal eyes are at higher risk of 
developing acute angle closure attacks.9,14 With the 
advancement in technology, anterior segment optical 
coherence tomography has been used to visualise 
and capture high-resolution images of the anterior 
segment of the eye. Another group of investigators 
found that smaller anterior chamber angles, shorter 
anterior chamber opening distances, steeper iris root 
curvatures, and a larger number of quadrants with 
angle closure were all the risk factors for acute angle 
closure attacks.15 In most acute angle closure cases, 
the aetiology is unknown. However, it is believed 
that external pharmacological and environmental 
stimuli play an important role in triggering such 
attacks in high-risk patients.16 Topical mydriatics 
(sympathomimetic or anticholinergic drugs) can 
trigger acute angle closure due to bunching up of 
the peripheral iris at the drainage angle (Figs 1 and 
2) and also through the mechanism of pupillary 
block when aqueous humour flow is blocked at the 
pupil border. Such effects may also ensue due to 
systemic and other topical drug treatments that have 
sympathomimetic (eg nasal decongestants, cocaine, 
phenylpropanolamine) or anticholinergic (eg 
muscarinic antagonists, imipramine, fluvoxamine) 
actions. They may also occur as idiosyncratic 
reactions to anti-histamines, sulpha-based drugs, 
antidepressants, and topiramate. Drug-induced 
acute angle closure attacks may affect either or both 
eyes simultaneously.17-20
Mechanisms of angle closure
Pupillary block
Pupillary block occurs when the iris border is in firm 
contact with the anterior lens surface. The contact 
area blocks the aqueous humour from flowing out 
Angle
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of the posterior chamber to the anterior chamber. 
The pressure that builds up in the posterior chamber 
pushes the iris root forward and eventually blocks the 
irido-corneal angle. Pupillary block usually occurs 
when the pupil is mid-dilated, as in this condition, 
the force of contact between the posterior iris and 
anterior lens is greatest.21 Interestingly, the iris 
volume increases in the narrow angle fellow eyes of 
patients who have a previous attack, but is decreased 
in open-angle eyes after pupil dilation. This increase 
in iris volume is associated with further narrowing of 
the angle.22 In other words, narrow angle eyes with an 
iris volume increase after dilatation are at higher risk 
of developing acute angle closure; the risk is highest 
when the pupil is mid-dilated.
Other angle closure mechanisms
Besides pupillary block, other mechanisms also exist 
that can close the drainage angle. The position of 
the ciliary body and the thickness of the lens play 
a contributory role in the development of angle 
closure.23,24 Subjects with an anterior position of the 
ciliary body (plateau iris configuration) or a thicker 
crystalline lens are prone to develop angle closure. 
There may be a combination of all the above factors 
in the development of angle closure. In some cases, 
uveal effusion can cause forward displacement of 
the iris-lens diaphragm resulting in angle closure. 
Uveal effusion refers to an abnormal collection 
of fluid in the suprachoroidal space, pushing the 
ocular tissues especially the iris and the lens to a 
more anterior position. Uveal effusion may occur in 
ocular inflammation, after ocular laser treatment or 
intraocular surgery. 
Drugs causing acute angle closure
Most systemic drug profiles listing glaucoma as a 
contra-indication or an adverse effect are concerned 
with inducing acute angle closure. Several classes 
of drugs have potential to trigger an acute attack of 
angle closure.
Topical mydriatics
Topical mydriatics that dilate the pupils and 
cycloplegics that relax the ciliary muscle are mainly 
required for detailed fundus examination in out-
patient clinics and during surgery, refraction and 
treatment for amblyopia. They are also used in the 
management of uveitis to prevent adhesion of the iris 
to the lens (posterior synechiae). Their cycloplegic 
effect can reduce the ocular pain and photophobia in 
ocular inflammatory diseases. Atropine, homatropine, 
cyclopentolate and tropicamide possess anti-
cholinergic properties, while phenylephrine has 
sympathomimetic properties. The overall frequency 
of topical mydriatic-induced acute angle closure 
attacks is around 0.03% (in white subjects aged >55 
years).25,26 It is less than 1% even in subjects with 
shallow anterior chamber/occludable angles and is 
less than 0.1% in Asians.27
Anticholinergic drugs
Anticholinergic agents block the neurotransmitter 
acetylcholine in the central and the peripheral 
nervous system. They inhibit the parasympathetic 
nerve transmission by blocking the acetylcholine 
receptors resulting in paralysis of smooth muscles 
present in the gastro-intestinal and urinary tracts, 
lungs, and elsewhere. Ipratropium bromide is used 
for the treatment of chronic obstructive pulmonary 
disease and acute asthma. It blocks the muscarinic 
acetylcholine receptors in the smooth muscles of these 
airways thus opening them up. Their anticholinergic 
effect also acts on the iris smooth muscle, resulting 
in pupil dilatation. Ipratropium bromide is often 
used in combination with β2 adrenoceptor agonists. 
There have been numerous reports on the induction 
of acute angle closure attack following the use of 
nebulised ipratropium bromide in combination 
with β2 agonists.28-36 Anticholinergic drugs are also 
used for the treatment of gastro-intestinal disorders, 
Parkinson’s disease, and genitourinary disorders. 
Atropine belongs to this class of drugs and is 
used systemically to treat bradycardia in patients 
undergoing general anaesthesia. It is one of the 
most common systemically administered drugs 
that induces acute angle closure attacks, and has 
been reported to be the possible cause in patients 
undergoing orthopaedic, cardiac, and oral surgery 
under general anaesthesia.37-39
Adrenergic agents
These include drugs used topically such as 
phenylephrine eye drops, nasal ephedrine, 
nebulised salbutamol, and given systemically such 
as epinephrine in the treatment of anaphylactic 
shock. Bronchodilators administered in nebulised 
form have been reported to precipitate bilateral 
acute angle closure attack in a patient suffering from 
acute bronchitis who eventually went blind despite 
medical and surgical interventions.40 
Drugs for upper respiratory infections
Cough mixtures and anti-cold medications contain 
anticholinergic and epinephrine ingredients, both of 
which have pupillodilating effects. Lai et al12 reported 
that 24% of patients suffering from acute angle 
closure attacks had upper respiratory infections, 
36% of whom took anti-cough mixtures prior to the 
attack. Rudkin et al41 reported a patient with bilateral 
acute angle closure attack after taking an over-the-
counter cold and flu medications that contained 
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active ingredients of atropa belladonna which was a 
herb with anticholinergic properties. The diagnosis 
of acute angle closure may be missed in these 
patients because symptoms like red eye, ocular 
pain, and headache may be mistaken as symptoms 
associated with upper respiratory tract infections. 
Onset of visual difficulty and the presence of a semi-
dilated pupil may be clues to an attack of acute angle 
closure.
Anti-depressants
Tricyclic antidepressants (TCAs) like imipramine 
have been widely used in the past and are still used 
occasionally for the treatment of depressive illness. 
Their anticholinergic properties can precipitate acute 
angle closure attack in predisposed individuals.42-44 
Although selective serotonin reuptake inhibitors 
(SSRIs) and serotonin-norepinephrine reuptake 
inhibitors have largely replaced TCAs, several 
of these agents like citalopram, paroxetine, and 
venlafaxine that increase the body serotonin levels 
may cause mydriasis. Acute angle closure has also 
been reported in patients receiving these classes 
of anti-depressants.19,45-48 The pathophysiological 
basis for acute angle closure in relation to SSRI anti-
depressant medications remains unclear. Citalopram 
may have a direct action on the iris or ciliary body 
muscles through serotonergic or anticholinergic 
mechanisms or both. Various reported cases highlight 
the importance of awareness of acute angle closure 
in psychiatric patients after the prescription of these 
classes of anti-depressants.
Anti-convulsants
Topiramate is a sulphamate-substituted monosaccharide 
used in the treatment of seizures, and in the 
prophylaxis of migraine. A few reports suggest 
an association between topiramate therapy and 
acute angle closure.49-52 One report documented 
uveal effusion in both eyes causing bilateral acute 
angle closure in a 40-year-old woman after taking 
oral topiramate for 10 days, which resolved after 
discontinuation of the drug. Topiramate causes 
ciliary body oedema, uveal effusion and relaxation of 
the zonules, resulting in a forward shift of the iris-
lens apparatus thus closing the angle abruptly. As 
the mechanism of topiramate-induced angle closure 
does not involve any pupillary block, standard 
treatments for acute angle closure (peripheral 
iridectomy and topical miotics) are not effective in 
this type of angle closure glaucoma. Fortunately, this 
type of drug-induced acute angle closure is rare.
Anti-histamines
Anti-histamines such as diphenhydramine, 
chlorpheniramine, and loratadine block the effects 
of histamine released by the body in response 
to allergen exposure. Their mild anticholinergic 
pharmacological effect may induce mydriasis and 
precipitate acute angle closure in predisposed 
patients.53 
Drugs used during general anaesthesia 
Acute angle closure is a rare complication of general 
anaesthesia. There have been case reports on 
unilateral or bilateral acute angle closure attacks 
following general anaesthesia.54,55 In one instance, 
there was bilateral acute angle closure after cervical 
spine surgery under general anaesthesia in a 
hypermetropic patient, for which the likely trigger 
was use of ephedrine, but nefopam administration 
and the prone position during surgery could also 
have been implicated.56 As already discussed, anti-
muscarinic agents, such as atropine and ipratropium 
bromide that are used as pre-anaesthetic medications, 
can cause pupil dilatation and precipitate an attack 
of acute angle closure. Moreover, salbutamol, a β2 
adrenoceptor agonist can compound the problem 
as it increases aqueous humour production and thus 
acts synergistically with anti-muscarinic agents to 
raise the IOP. It is important to note that iatrogenic 
acute angle closure attack under these circumstances 
can be masked by the general anaesthesia and timely 
treatment to prevent visual loss is critical. 
Sulphamate derivative 
Sulpha-based drugs like acetazolamide, 
hydrochlorothiazide, cotrimoxazole, and topiramate 
that have no pupillodilating effect can still induce 
acute angle closure by causing ciliary body oedema 
and forward movement of the iris-lens diaphragm.18,20 
They induce ‘non-pupillary block’ angle closure as an 
idiosyncratic reaction in patients with narrow as well 
as open angles. There has been an interventional case 
report of a 76-year-old man who developed bilateral 
angle closure attacks with extensive choroidal 
detachment following administration of oral 
acetazolamide, immediately after routine cataract 
extraction and intraocular lens implantation.57 Rapid 
clinical improvement occurred after cessation of 
acetazolamide use and high-dose intravenous steroid 
therapy. Although extremely rare, this adverse effect 
should be considered in patients who develop acute 
bilateral angle closure and choroidal effusion after 
cataract surgery. Ironically, acetazolamide, an IOP-
lowering drug that is used for the treatment of all 
kinds of glaucoma, can itself induce acute angle 
closure through an idiosyncratic reaction.
Miscellaneous drugs
Botulinum toxin is widely used nowadays for medical 
and cosmetic treatment. Periocular injection of 
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botulinum toxin for the treatment of blepharospasm 
has been reported to precipitate an acute attack of 
angle closure. It was believed that the toxin diffused 
back from the site of injection to the ciliary ganglion 
inhibiting the pupillary sphincter, which resulted in 
pupil dilatation and caused an acute closure of the 
angle.58 
 Cabergoline, an ergot derivative, is a potent 
dopamine receptor agonist. It is frequently used as a 
first-line agent in the management of prolactinomas. 
There has been a case report of bilateral acute 
angle closure attack after its oral use for the 
treatment of galactorrhoea.59 Ophthalmic ultrasound 
demonstrated effusions in the vicinity of the ciliary 
body as well as an anterior rotation of the ciliary body 
as the possible causes of acute angle closure.
 Sympathomimetic drugs such as 
phendimetrazine and ephedrine that are used as 
postoperative anorexiants may cause ciliochoroidal 
effusion, making shallow anterior chamber, resulting 
in acute angle closure.60 
Conclusion
Acute angle closure is a blinding eye emergency. 
Visual loss is preventable if the condition is recognised 
early and managed properly. Many systemic drugs 
used in various specialties may precipitate acute 
angle closure attacks that can involve both eyes 
simultaneously. Unfortunately the ocular symptoms 
may be masked by symptoms of the underlying 
systemic disease or the patients may be under 
general anaesthesia. Female gender, a history of 
intermittent blurring of vision with or without ocular 
pain and headache, and a sensation of seeing halos 
should alert physicians that the patient may be at risk 
of developing acute angle closure. Clinicians should 
be aware and mindful of possible drug-induced 
acute angle closure and the symptoms during an 
attack. Whenever there is doubt, ophthalmological 
consultation is recommended. 
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